Royalty Pharma plc (RPRX) · Nov 4, 2026 · Earnings

Royalty Pharma earnings raise 2026 guidance as royalties grow 9%

Guidance raised — FY Portfolio Receipts raised to $3.50B-$3.55B from $3.40B-$3.50B

Royalty Pharma earnings show 9% royalty-receipt growth and another 2026 guidance increase, though a pelacarsen impairment drags net income.

Royalty Pharma is a royalty-collection and life-sciences funding platform, using cash from marketed drugs to acquire additional royalties and co-fund development-stage medicines. Before this release, the business was already on a strengthening track: it had raised 2026 Portfolio Receipts guidance twice, most recently to $3.40 billion-$3.50 billion, while expanding capital deployment and its development pipeline.

The core operating trend remains healthy. Q3 Portfolio Receipts rose 9% to $890 million, led by Tremfya, Voranigo, Evrysdi and the growing Imdelltra royalty stream; Royalty Receipts also rose 9% to $883 million. That is consistent with the trajectory investors had already seen in Q2, rather than a sudden change in the business.

Q3 2026Q3 2025Comparison
Portfolio Receipts (Financial Highlights)$890M (+9%)$814M
Royalty Receipts (Portfolio Receipts)$883M (+9%)$811M
Adjusted EBITDA (Financial Highlights)$840M (+8%)$779M
Portfolio Cash Flow (Financial Highlights)$673M (+2%)$657M
Net cash from operating activities (Cash Flow statement)$686M (-2%)$703M
FY Portfolio Receipts guidance (Guidance table)$3.50B-$3.55BPrior: $3.40B-$3.50B

The meaningful surprise is another guidance increase, not the quarter itself. Management lifted the full-year Portfolio Receipts range by $50 million at both ends, implying 10%-11% Royalty Receipts growth for 2026. Because guidance had already been raised twice in 2026, this is a continuation of the positive operating story rather than a rewrite of it.

The portfolio is producing growth, but concentration and setbacks still matter. Promacta receipts fell 75% amid U.S. generic competition and Imbruvica declined 24%, while Royalty Pharma recorded a $150 million non-cash impairment tied to pelacarsen after its Phase 3 trial missed its primary endpoint. 〔0〕 Those items explain why consolidated net income attributable to Royalty Pharma fell to $145 million from $284 million despite higher royalty receipts; the impairment is non-cash, but it confirms that development-stage portfolio risk is real.

Cash generation is adequate but less impressive than the headline growth. Adjusted EBITDA rose 8%, yet Portfolio Cash Flow increased only 2% because net interest paid rose to $167 million from $123 million, and operating cash flow slipped 2%. The company also ended the quarter with $8.8 billion of debt and $514 million of cash, although it repaid a $380 million term loan during the quarter.

Capital deployment keeps the longer-term growth engine active. Royalty Pharma deployed $362 million in Q3 and had announced up to $1.9 billion of transactions by November 3, including royalties on Zoryve and Mimrylo and funding tied to cliramitug. That supports the strategy of replenishing future royalty growth, but the returns remain dependent on commercialization and clinical outcomes rather than current-quarter execution alone.

Bottom line: This is a modestly better quarter for an already improving business, chiefly because guidance was raised again. The positive signal is real, but it advances the existing story rather than changing it, and the pelacarsen impairment and higher interest burden keep the read from being stronger.

What to watch next

Q4 results and 2027 guidance, early 2027

Original filing on SEC EDGAR

More Royalty Pharma plc news

Royalty Pharma earnings raise 2026 guidance as royalties grow 9% | RPRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.